Fig. 3From: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimodChanges in the levels of CCL2 in the serum during the whole study in each individual patient. The recorded baseline values ranged between 427 and 1309 pg/mL. A reduction was observed in 7 out of 9 patients during treatment; the mean (shown in red) reduction was 18% (p = 0.07)Back to article page